The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Cevostamab plus pomalidomide after BCMA-directed therapy in R/R multiple myeloma
Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, discusses the potential role of cevostamab plus pomalidomide following BCMA-directed therapy in patients with relapsed/refractory (R/R) multiple myeloma. He highlights the potential efficacy of the combination after BCMA antibody-drug conjugates or CAR T-cell therapy, while noting lower response rates following BCMA bispecific antibodies and the potential impact of immune dysfunction in this setting. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Cervosumab is a bispecific antibody targeting FcRH5, and we’re aware that expression is not altered by previous exposure to a BCMA-targeted therapy. This is very important because patients who are failing a BCMA CAR T-cell or, for example, belantamab mafodotin will retain FcRH5 expression and therefore could be candidates for cevostamab-based treatments. What we know from the CAMMA 1 clinical trial is that cevostamab plus pomalidomide is highly effective with high response rates and durable responses, as well as being a tolerable combination...
Cervosumab is a bispecific antibody targeting FcRH5, and we’re aware that expression is not altered by previous exposure to a BCMA-targeted therapy. This is very important because patients who are failing a BCMA CAR T-cell or, for example, belantamab mafodotin will retain FcRH5 expression and therefore could be candidates for cevostamab-based treatments. What we know from the CAMMA 1 clinical trial is that cevostamab plus pomalidomide is highly effective with high response rates and durable responses, as well as being a tolerable combination. And so we believe that cevostamab plus pomalidomide could well be an effective salvage therapy for patients who are failing either a BCMA CAR T-cell or a BCMA antibody drug conjugate. I would, however, be a little bit careful following a BCMA bispecific antibody because the CAMMA 1 study also demonstrated that the response rate for cevostamab following a BCMA bispecific was just 10%. Now, the reason for that is probably due to immune T-cell deregulation as opposed to target change. So really, the Cevopom combination is best being used post-Belantamab or BCMA CAR T-cells.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
